Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Pre-Open Stock Movers 04/13: ATRS, SRRA, STAB Higher; NSTG, LQDA, BBBY Lower

Apr 13, 2022 09:18
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

 

 
CRDF
-4.47%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BCTX
-0.13%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
HLMN
+1.04%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GOEV
+0.83%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LQDA
-3.18%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SRRA
+0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Pre-Open Stock Movers:

Antares Pharma , Inc. (NASDAQ:ATRS) 49% HIGHER; Halozyme (NASDAQ:HALO) Therapeutics, Inc. (HALO) agreed to acquire the company for $5.60 per share in cash, or $960 million.

Sierra Oncology (NASDAQ:SRRA), Inc (Nasdaq: SRRA) 38% HIGHER; GlaxoSmithKline (NYSE:GSK) plc (GSK) will acquire the company for $55 per share, or $1.9 billion.

NanoString Technologies, Inc. (NSTG) 33% LOWER; announced preliminary total product and service revenue of approximately $31 million for the first quarter, versus prior guidance of $34-$38 million.

Statera Biopharma, Inc. (Nasdaq: STAB) 18% HIGHER; Enters deal with Coeptis Therapeutics to sell rights to toll-like receptor 5 (TLR5) agonist platform.

Liquidia Corporation (LQDA) 13% LOWER; priced 9,803,922 share offering at $5.10.

BriaCell Therapeutics (BCTX) 13% HIGHER; FDA granted Fast Track status to lead candidate, Bria-IMT;

Hillman Solutions Corp. (Nasdaq: HLMN) 11% LOWER; priced upsized 13,000,000 share secondary offering at $10.

Canoo Inc. (Nasdaq: GOEV) 8% HIGHER; selected by NASA to deliver multiple customized all-electric LV models to NASA by June 2023.

Bed Bath & Beyond (BBBY) 8% LOWER; reported Q4 EPS of ($0.92), $0.95 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $2.05 billion versus the consensus estimate of $2.07 billion.

VerifyMe, Inc. (VRME) 7% LOWER; entered into a securities purchase agreement with certain accredited investors to purchase approximately $5.0 million of its common stock.

Delta Air Lines (NYSE:DAL) (DAL) 5% HIGHER; reported Q1 loss per share $1.23, versus the analyst estimate of -$1.27. Revenue for the quarter came in at $9.3 billion versus the consensus estimate of $8.92 billion.

PayPal Holdings, Inc. (NASDAQ:PYPL) 5% LOWER; CFO John Rainey leaves to join Walmart (NYSE:WMT).

Cardiff Oncology, Inc. (Nasdaq: CRDF) 4% LOWER; chief medical officer Katherine L. Ruffner, M.D. is leaving to pursue a new opportunity.

Affimed N.V. (Nasdaq: NASDAQ:AFMD) 3% HIGHER; priced 22,500,000 share offering at $4.

JPMorgan (NYSE:JPM) (JPM) 3% LOWER; posted Q1 EPS of $2.63,versus the consensus of $2.69. Revenue for the quarter came in at $30.7 billion versus the consensus estimate of $30.86 billion.

Pre-Open Stock Movers 04/13: ATRS, SRRA, STAB Higher; NSTG, LQDA, BBBY Lower
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email